InvestingPro offers 15+ additional premium tips and a comprehensive Pro Research Report for UNH, helping investors make more informed decisions. In other recent news, UnitedHealth Group's earnings and revenue figures have been a focal point for analysts. Raymond James has adjusted its future earnings per share (EPS) estimates downward, citing concerns over the quality and recurrence of earnings, particularly after excluding $4 billion in one-time gains from 2024. The revised estimates project an adjusted EPS of $20 for 2025 and $23 for 2026. Meanwhile, RBC Capital Markets reduced its price target for UnitedHealth to $355, while maintaining an Outperform rating, due to revised EPS estimates and valuation concerns amid increased Department of Justice (DOJ) activity. Wolfe Research, however, maintained its $501 price target and Outperform rating, despite the ongoing DOJ investigation into potential Medicare fraud.